Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02813902
Other study ID # 2016P001176
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date July 2019
Est. completion date May 2020

Study information

Verified date March 2019
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This proposal describes a pilot study to gather preliminary evidence of efficacy, tolerability and toxicity of oral PLE among a high-risk skin cancer population for the prevention of Actinic keratosis (AKs) and keratinocytes (KCs) to gain insight into optimal methods for recruitment, intervention development, data collection, and promoting protocol adherence prior to conducting a fully powered trial. The primary clinical outcome is AKs as measured by a clinical dermatologist, with skin cancer as a secondary clinical outcome. The investigators will also assess histologic markers of Ultra Violet (UV) damage, which have previously been shown to be reduced with oral PLE use in human studies, namely formation of UV-induced cyclo pyrimidine dimer positive cells and number of sunburn cells among epidermal keratinocytes. Results generated from this proposal will form the foundation of a fully powered clinical trial of the effect of PLE on the risk of AKs and KCs. The results may also provide information about this promising dietary supplement which may provide extra protection for a high-risk skin cancer population.


Description:

Polypodium leucotomos is a tropical fern, the extract of which has shown photoprotective effects in animal and human models, and is currently available as an over-the-counter dietary supplement. Polypodium leucotomos extract (PLE) has been shown in laboratory, animal, and clinical studies to serve as a potent antioxidant that helps mitigate UV-induced damage by scavenging free radicals and reactive oxygen species. Oral consumption of PLE in human studies has been shown to significantly reduce the number if UV-induced sunburn cells and DNA damage, and to inhibit photosensitization. Importantly, PLE appears to be exceptionally well-tolerated with no serious reported adverse side effects.

PLE has been studied in numerous trials for many conditions, including skin diseases. Doses up to 1200 mg per day have been used in clinical studies, though doses for prevention of sun-damage are typically in the range of 480 mg per day. To date, no serious adverse effects have been clearly attributed to the use of PLE (this high tolerability is one of the reasons for the great interest in the clinical use of PLE). Oral consumption of other fern species, such as Polypodium vulgare, have been associated with low blood pressure and increased heart rate. On theoretical grounds, similar side effects may be possible with PLE.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 2020
Est. primary completion date May 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Must be male or female and at least 18 years of age.

- Female patients must be of:

- Non-childbearing potential;

- Childbearing potential, provided negative urine pregnancy test and using effective contraception.

- Dermatologist-rendered diagnosis of AK in the past 2 years.

Exclusion Criteria:

- History of >2 skin cancers in the past 5 years

- History of dementia

- Cardiovascular disease, defined as Blood Pressure (BP) <90/60 or Heart rate (HR) >110 in the past year or a history of myocardial infection

- Inflammatory bowel disease/irritable bowel syndrome

- Treatment with Fluorouracil, imiquimod, diclofenac, or photodynamic therapy in the past 8 weeks

- Intention to seek more aggressive AK therapy such as photodynamic therapy, laser surgery in next 12 months

- Serious psychological illness

- History of alcohol or drug abuse

- Any disease or condition which would interfere with study participation or unduly increase risk.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Heliocare with Fernblock PLE technology
240 mg taken orally daily over the course of 1 year
Other:
Sugar Pill
A pill that appears similar to the supplement

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Total number of new clinically visable AKs as measured by a full skin exam performed by a blinded, board certified dermatologist (Dr. Asgari). one year
Secondary Histologic presence of UV-induced cyclobutane pyrimidine dimer positive cells one year
Secondary Degree of solar elastosis assessed using Verhoeff stain on biopsy specimens obtained from punch biopsy one year
Secondary Counts of sunburnt cells in sun exposed skin one year
See also
  Status Clinical Trial Phase
Completed NCT00027586 - Imatinib Mesylate in Treating Patients With Metastatic Melanoma Phase 2
Not yet recruiting NCT02230462 - Patient Satisfaction After Facial Reconstruction N/A
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Completed NCT00224744 - Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage Phase 3
Completed NCT03132012 - Skin Health in Young Adults - Preventing Indoor Tanning and Promoting Sun Protection N/A
Terminated NCT00865878 - ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients Phase 2
Not yet recruiting NCT05359419 - Comparison of Two Modes of Photodynamic Therapy for the Treatment of Actinic Keratosis on the Upper Extremities Phase 4
Active, not recruiting NCT00001813 - Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
Completed NCT02046811 - Reducing Skin Cancer Risk in Childhood Cancer Survivors N/A
Completed NCT02147080 - A Tailored Internet Intervention to Reduce Skin Cancer Risk Behaviors Among Young Adults N/A
Completed NCT00007631 - Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer Phase 3
Completed NCT00847912 - CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Phase 4
Recruiting NCT02836548 - HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma Phase 1/Phase 2
Completed NCT01482104 - New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC) N/A
Enrolling by invitation NCT04630886 - Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery Early Phase 1
Completed NCT03012581 - Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types Phase 2
Not yet recruiting NCT02408835 - Negative Pressure Wound Therapy in Groin Dissection N/A
Completed NCT00204789 - Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients Phase 2
Completed NCT02310503 - Spanish Registry of Mohs Surgery
Active, not recruiting NCT04267861 - M7824 Related Adverse Effects in Adults With Cancer